Laurel Wealth Advisors Inc. lowered its stake in Amarin Co. plc (NASDAQ:AMRN) by 2.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 83,610 shares of the biopharmaceutical company’s stock after selling 2,440 shares during the quarter. Laurel Wealth Advisors Inc.’s holdings in Amarin were worth $1,621,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of AMRN. Rubric Capital Management LP increased its holdings in shares of Amarin by 67.2% during the first quarter. Rubric Capital Management LP now owns 2,250,000 shares of the biopharmaceutical company’s stock worth $46,710,000 after buying an additional 904,624 shares in the last quarter. EULAV Asset Management increased its holdings in Amarin by 12.3% in the second quarter. EULAV Asset Management now owns 1,740,000 shares of the biopharmaceutical company’s stock valued at $33,739,000 after purchasing an additional 190,000 shares during the period. Federated Investors Inc. PA increased its holdings in Amarin by 56.9% in the first quarter. Federated Investors Inc. PA now owns 1,612,324 shares of the biopharmaceutical company’s stock valued at $33,472,000 after purchasing an additional 585,000 shares during the period. Pictet Asset Management Ltd. bought a new stake in Amarin during the second quarter valued at $27,928,000. Finally, Frontier Capital Management Co. LLC boosted its position in Amarin by 395.7% during the first quarter. Frontier Capital Management Co. LLC now owns 1,021,731 shares of the biopharmaceutical company’s stock valued at $21,211,000 after acquiring an additional 815,616 shares during the last quarter. Institutional investors own 47.94% of the company’s stock.

Shares of AMRN stock traded up $0.08 on Friday, reaching $16.83. 69,637 shares of the company were exchanged, compared to its average volume of 6,576,359. The company has a market cap of $5.83 billion, a price-to-earnings ratio of -42.87 and a beta of 1.27. The company has a 50-day moving average of $16.08 and a 200-day moving average of $18.42. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.01 and a quick ratio of 1.76. Amarin Co. plc has a one year low of $2.65 and a one year high of $23.91.

Amarin (NASDAQ:AMRN) last released its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.01. The company had revenue of $100.40 million for the quarter, compared to analysts’ expectations of $99.54 million. Amarin had a negative net margin of 27.51% and a negative return on equity of 111.75%. The business’s revenue was up 90.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.10) EPS. As a group, sell-side analysts predict that Amarin Co. plc will post -0.2 EPS for the current year.

AMRN has been the topic of a number of research analyst reports. Cantor Fitzgerald set a $35.00 price target on shares of Amarin and gave the company a “buy” rating in a research report on Tuesday, September 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Amarin in a research report on Thursday, August 1st. Svb Leerink initiated coverage on shares of Amarin in a research report on Wednesday, August 14th. They set an “outperform” rating and a $26.00 price target on the stock. Leerink Swann set a $26.00 price target on shares of Amarin and gave the company a “buy” rating in a research report on Tuesday. Finally, Roth Capital set a $31.00 price target on shares of Amarin and gave the company a “buy” rating in a research report on Friday, September 6th. Three analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Amarin has a consensus rating of “Buy” and a consensus price target of $29.50.

In other Amarin news, insider Aaron Berg sold 113,195 shares of the stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $18.59, for a total value of $2,104,295.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Wayne Kalb sold 50,000 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $19.67, for a total transaction of $983,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 659,202 shares of company stock worth $13,058,754 in the last three months. Insiders own 2.75% of the company’s stock.

Amarin Profile

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

See Also: Growth Stocks

Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.